Schizophrenia

Miami, FL

30 Schizophrenia Trials near Miami, FL

Power is an online platform that helps thousands of Schizophrenia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

522 Participants Needed

This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

432 Participants Needed

KarXT for Schizophrenia

Coral Gables, Florida
This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.
Stay on current meds
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

280 Participants Needed

Valbenazine for Schizophrenia

Coral Gables, Florida
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

442 Participants Needed

This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:10 - 17

236 Participants Needed

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:12 - 17

100 Participants Needed

This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

850 Participants Needed

This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:18 - 60

360 Participants Needed

The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.
No Placebo Group

Trial Details

Trial Status:Recruiting

60 Participants Needed

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 51

1361 Participants Needed

This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Age:18 - 65

67 Participants Needed

This trial is testing a new medication called TV-44749 to see if it helps adults with schizophrenia, especially those with worsening symptoms. The medication likely works by balancing brain chemicals to reduce symptoms. The study will last over a year, with different phases to test both its effectiveness and safety.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 64

675 Participants Needed

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17

500 Participants Needed

This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:5 - 17

310 Participants Needed

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting

450 Participants Needed

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17

220 Participants Needed

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

284 Participants Needed

The study design is a de-escalation of current atypical AP treatment to X/T at a maintenance dose of X/T established either at 100 mg xanomeline/20 mg trospium chloride BID (total daily dose 200 mg xanomeline/40 mg trospium chloride) or 125 mg xanomeline/30 mg trospium chloride BID (total daily dose 250 mg xanomeline/60 mg trospium chloride) based on participants' clinical response and/or tolerability. While the package insert for X/T provides guidance for clinicians on dosing, this study is designed to assess how transitioning will occur in the "real world" situation.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:18 - 65

100 Participants Needed

LB-102 for Schizophrenia

Miami Lakes, Florida
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 55

350 Participants Needed

ALTO-101 for Schizophrenia

Hollywood, Florida
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 55

82 Participants Needed

Why Other Patients Applied

"I really would love to be normal. A functioning part of society. It is very hard to hold a job with this condition. I need to be steady. I do NOT like my current meds or ones I've tried before, so new therapies are of interest to me. "

EC
Bipolar Disorder PatientAge: 42

"I would like to get a medication that has fewer side effects than the ones I've used. Many antipsychotics just make me numb or flat and I can't really think. Also I like the idea of helping in research to find better medications for schizephrenia."

VT
Schizophrenia PatientAge: 60

"I’ve been diagnosed with Schizoaffective Disorder for over 5 years now and not found much relief in medication. One I’ve tried helped a bit but the side affects were overwhelming. Hoping I can gain some relief from this disorder and help advance research as well!"

MX
Schizophrenia PatientAge: 44

"I’ve been treated over the years from my late teens. I’ve been through many therapists for my bipolar and my anxiety. None of it’s helped. I gave up when I was 27. It’s been 5 years of struggling day by day. My fiancé has finally suggested I look into trying to get help so I’m hoping this clinical trial will help."

WZ
Schizophrenia PatientAge: 32

"I've tried lots of drugs and I still have symptoms. I'm not sure of my reality because the things I see and hear are still active. Maybe this will help one way or the other. I would be glad to help others in the future by testing a medication as well."

CY
Schizophrenia PatientAge: 62
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:10 - 17

140 Participants Needed

The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia. Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. The total duration of participation in the trial for each participant is planned to be approximately 21 weeks.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 64

116 Participants Needed

KarXT for Schizophrenia

Hollywood, Florida
The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 65

173 Participants Needed

This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:18 - 65

690 Participants Needed

This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.

Trial Details

Trial Status:Recruiting
Age:18 - 55

234 Participants Needed

To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:13 - 17

295 Participants Needed

This trial is testing whether clozapine can reduce violent behavior more effectively than usual treatments in adults with schizophrenia who have recently been violent. Clozapine helps by balancing brain chemicals to manage symptoms. The study will last for several months and include regular medical check-ups. Clozapine has been shown to reduce violent and aggressive behavior in patients with schizophrenia, especially those who are treatment-resistant.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 65

280 Participants Needed

The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 60

524 Participants Needed

The current study examines the efficacy of a cognitive training intervention for improving emotion regulation in psychotic disorders. it is hypothesized that the cognitive training program will enhance prefrontal activation, leading to enhanced emotion regulation.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60

70 Participants Needed

This research project will explore negative symptoms of schizophrenia, such as motivational deficits, by examining the relationship between inflammation and reward-related brain regions. To accomplish this, we will administer a single infusion of either the anti-inflammatory medication infliximab or placebo (n=10 per group) to patients with high inflammation. This study is important because schizophrenia can be a chronic and debilitating neuropsychiatric disorder and negative symptoms are some of the most difficult aspects of schizophrenia associated with worst functional outcomes. These symptoms do not typically respond to antipsychotic therapies, and as such, there are no current medications to treat negative symptoms.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 45

20 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Schizophrenia clinical trials in Miami, FL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Schizophrenia clinical trials in Miami, FL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Schizophrenia trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL for Schizophrenia is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Schizophrenia medical study in Miami, FL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Schizophrenia clinical trials in Miami, FL?

Most recently, we added NBI-1117568 for Schizophrenia, Xanomeline + Trospium for Schizophrenia and SEP-363856 for Schizophrenia to the Power online platform.

Why is schizophrenia more common now?

Most studies show the yearly number of new schizophrenia cases hasn’t skyrocketed; it only feels more common because doctors now catch milder cases and people with the illness live longer, so more are counted at any one time. Modern lifestyle changes—growing up in crowded cities, high-potency cannabis use, migration stress, older parenthood, and ongoing poverty—do add modest risk for certain groups, nudging overall figures upward. Recognising these drivers guides prevention efforts like early screening, substance-use education, urban social support, and good prenatal care.

What is the best injection for schizophrenia?

There isn’t one “best” injection for everyone with schizophrenia. Doctors usually choose among long-acting injectables such as paliperidone (monthly to every 6 months), aripiprazole (monthly or every 2–3 months) or risperidone (every 2 weeks to monthly) based on which oral version has helped you before, how often you can come for shots, and which side-effects you’re most sensitive to. Your psychiatrist will review these factors—plus cost, other health conditions and personal preference—to decide which LAI is the safest and most effective fit for you.

Who is most likely to recover from schizophrenia?

Research shows the best odds of meaningful recovery occur in people who get treatment quickly after their first symptoms, keep taking medication and using psychological/rehab supports, avoid alcohol or drugs, and have steady family or community support; women and those whose illness starts later in their 20s also tend to fare somewhat better, but these fixed factors matter less than the modifiable ones above. In short, while anyone with schizophrenia can improve, the combination of early intervention, sticking with care, healthy lifestyle, and strong social ties makes the biggest difference in who recovers.

Is schizophrenia inherited from mother or father?

Schizophrenia risk is passed down through many genes that you receive from both parents, and large studies do not show a consistent advantage of either the mother’s or the father’s side. Compared with the 1 % lifetime risk in the general population, the chance rises to about 10 % if one parent has schizophrenia and up to 40 % if both do; factors such as pregnancy complications, cannabis use, severe stress, or very advanced paternal age can add to that risk. Families with a history of the illness may benefit from genetic counselling and early mental-health check-ups during adolescence so any warning signs can be managed promptly.

How is schizophrenia viewed in China?

China does not have a single view of schizophrenia: in big cities many people now regard it as a treatable brain disorder, but in rural areas it may still be linked to spirit possession or seen as a source of family “shame,” so relatives often hide the illness and shoulder most care. High stigma persists because unusual behaviour is felt to threaten the family’s “face,” yet government programs such as the nationwide 686 follow-up system and the 2013 Mental-Health Law are expanding hospital care, community visits, and public education. Overall, attitudes are gradually shifting toward acceptance, but progress is uneven and support for both patients and their families remains a work in progress.

Are there any clinical trials being done for schizophrenia?

Yes—dozens of studies are actively recruiting worldwide, ranging from novel medicines like KarXT (muscarinic M1/M4 agonist), ulotaront (TAAR1 agonist), and roluperidone (aimed at negative symptoms) to long-acting weekly risperidone implants (TV-46000) and app-based cognitive programs. You can see real-time listings, eligibility criteria, and locations by typing “schizophrenia” into ClinicalTrials.gov or the EU Clinical Trials Register and then reviewing the options with your psychiatrist to weigh potential benefits, risks, and travel demands.

What is the biggest problem of schizophrenia?

Schizophrenia isn’t defined by one “biggest problem”; clinicians group its effects into positive symptoms (hallucinations/delusions), disorganization, negative symptoms (loss of drive, social withdrawal) and cognitive deficits. Studies show that after acute psychosis is controlled, the lasting obstacles to working, studying and maintaining relationships are usually the negative and cognitive symptoms, so effective care pairs antipsychotic medication with therapies and skills training that rebuild motivation, thinking and daily-living abilities.

Who has the highest rate of schizophrenia?

Worldwide, the single highest recorded rates occur in young adult Black Caribbean or Black African men who are migrants (or children of migrants) living in large urban areas; their chance of developing schizophrenia can be 4- to 9-times higher than that of white native-born residents. In general, men have a modestly higher risk than women (about 1.4 : 1), but factors such as minority or migrant status and growing up in a high-density city raise risk far more than sex alone.

What's the latest schizophrenia can develop?

Most people who develop schizophrenia do so between their late teens and early 30s, but experts recognise “late-onset” cases appearing at 40-60 and a rarer “very-late-onset schizophrenia-like psychosis” beginning after 60. Because psychosis this late in life is uncommon and can mimic problems such as dementia, stroke, or severe depression, anyone with new hallucinations or delusions at these ages should be evaluated promptly by a mental-health professional and a physician to sort out the cause and start the right treatment.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security